CN104887785A - Drug for treating chronic eczema of skin - Google Patents
Drug for treating chronic eczema of skin Download PDFInfo
- Publication number
- CN104887785A CN104887785A CN201510265782.6A CN201510265782A CN104887785A CN 104887785 A CN104887785 A CN 104887785A CN 201510265782 A CN201510265782 A CN 201510265782A CN 104887785 A CN104887785 A CN 104887785A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- drug
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a drug for treating chronic eczema of skin. The drug is prepared from the following raw pharmaceutical materials in parts by weight: 20-30 parts of radix sanguisorbae, 20-30 parts of lithospermum erythrorhizon, 30-40 parts of artemisia annua, 20-30 parts of poria cocos, 10-20 parts of lonicera japonica, 10-20 parts of herba portulacae, 10-20 parts of atractylodes macrocephala, 20-30 parts of asarum, 5-10 parts of cnidium monnieri and 10-20 parts of flavescent sophora root. Proven by clinical tests, the drug has the beneficial effects that the effect on treating chronic eczema of skin is very remarkable, and the treatment effect is definite; due to external application, the side effect is low; and the traditional Chinese medicinal materials which are relatively economical and practical are selected, so that the drug is more easily accepted by patients.
Description
Technical field
The present invention relates to Chinese medicine composition, be specifically related to the medicine for the treatment of skin chronic eczema.
Background technology
Eczema is the reaction of a kind of scytitis, is commonly encountered diseases, the frequently-occurring disease of department of dermatologry.Divide acute, subacute, chronic three phases.Acute stage, tool oozed out tendency, and chronic phase then infiltrates, plumpness.Some patient directly translates into chronic eczema.Skin lesion has the features such as pleomorphism, symmetry, pruritus and easy recurrent exerbation.
Eczematosis, because of complexity, is often internal and external reasons interaction result.Endogenous cause of ill is as chronic digestive system disease, psychentonia, insomnia, overtired, emotion changes, endocrine disturbance, infection, dysbolism etc., and exopathogenic factor such as living environment, climate change, food etc. all can affect the generation of eczema.Environmental stimuli as daylight, cold, drying, sweltering heat, hot water is scalded and various animal skin, plant, cosmetics, soap, staple fibre etc. all can bring out.Therefore eczema is a kind of delayed allergy that the complicated inside and outside factor causes.
The medicine of current treatment eczema is various.Western medicine class drug main will adopt antianaphylactic treatment, does not have the curative effect of effecting a radical cure, and easily recurs and more or less has hormone composition, having side effect.The medicine of Chinese medicine class treatment eczema is also reported for work more, as patent CN104383087A, disclose a kind of medicine for the treatment of skin eczema, be made up of the material of following weight portion: Sabia parviflora Wall.ex Roxb 500-1000 part, Herba Fici Stenophyliae 700-1200 part, Herba Lycopodii Obscuri 500-1000 part, Herba Clematidis tanguticae 500-800 part, field Radix Arnebiae (Radix Lithospermi) 600-900 part, Caulis Arcangelisiae 500-800 part, northern Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 600-900 part, field fiber crops 500-1000 part, Herba Chloranthi Henryi (Herba Choranthi seu Lysimachiae) 600-900 part, Herba Saussureae gramineae 500-800 part, purslane speedwell Herba 500-800 part and Herba Rabdosiae Sculponeatae 500-900 part; Patent CN104306806A, disclose a kind of Chinese medicine composition for the treatment of eczema, be made up of the Chinese herb of following composition: Herba Schizonepetae 15-30 part, Radix Rehmanniae 10-20 part, Flos Chrysanthemi Indici 10-20 part, parching to brown Siberian cocklebur 8-15 part, Scorpio 2-5 part, Testa sojae atricolor 10-20 part, Radix Sophorae Flavescentis 10-20 part, Folium Isatidis 10-20 part, Herba Verbenae 15-25 part, Semen Coicis 10-20 part, Herba Taraxaci 5-15 part.But above-mentioned Chinese Herbs is general, be extremely necessary that effort research and development are evident in efficacy, the Chinese medicine composition of the treatment skin chronic eczema for the treatment of both the principal and secondary aspects of a disease.
Summary of the invention
The object of the invention is for deficiency of the prior art, a kind of medicine for the treatment of skin chronic eczema is provided.
The technical scheme that the present invention takes is:
Treat a medicine for skin chronic eczema, be made up of the crude drug of following weight portion: Radix Sanguisorbae 20-30 part, Radix Arnebiae (Radix Lithospermi) 20-30 part, Herba Artemisiae Annuae 30-40 part, Poria 20-30 part, Radix Ophiopogonis 10-20 part, Herba Portulacae 10-20 part, Rhizoma Atractylodis Macrocephalae 10-20 part, Herba Asari 20-30 part, Fructus Cnidii 5-10 part, Radix Sophorae Flavescentis 10-20 part.
As one preferably embodiment, be made up of the crude drug of following weight portion: Radix Sanguisorbae 25-30 part, Radix Arnebiae (Radix Lithospermi) 22-26 part, Herba Artemisiae Annuae 30-35 part, Poria 22-26 part, Radix Ophiopogonis 15-18 part, Herba Portulacae 15-18 part, Rhizoma Atractylodis Macrocephalae 12-16 part, Herba Asari 25-30 part, Fructus Cnidii 8-10 part, Radix Sophorae Flavescentis 15-20 part.
As a kind of more excellent embodiment, be made up of the crude drug of following weight portion: Radix Sanguisorbae 25 parts, Radix Arnebiae (Radix Lithospermi) 25 parts, Herba Artemisiae Annuae 35 parts, 24 parts, Poria, Radix Ophiopogonis 15 parts, Herba Portulacae 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Herba Asari 25 parts, Fructus Cnidii 9 parts, Radix Sophorae Flavescentis 18 parts.
Beneficial effect of the present invention is: Drug therapy skin chronic eczema effect of the present invention is very remarkable, determined curative effect, and be external, side effect is little, and the comparatively economical and practical Chinese crude drug that has drawn from, to be easier to accept by patient, patient also can prepare voluntarily.
Detailed description of the invention
Below detailed description of the invention provided by the invention is further described, but it is only preferred version, does not limit the scope of the invention.
embodiment 1
Radix Sanguisorbae 30 parts, Radix Arnebiae (Radix Lithospermi) 20 parts, Herba Artemisiae Annuae 40 parts, 20 parts, Poria, Radix Ophiopogonis 20 parts, Herba Portulacae 10 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Asari 20 parts, Fructus Cnidii 10 parts, Radix Sophorae Flavescentis 10 parts, 80 mesh sieves are crossed after co-grinding, add 10 times amount soak by water 5 hours, then add 5 times amount soak by water 3 hours, natural cooling.
embodiment 2
Radix Sanguisorbae 20 parts, Radix Arnebiae (Radix Lithospermi) 30 parts, Herba Artemisiae Annuae 30 parts, 30 parts, Poria, Radix Ophiopogonis 10 parts, Herba Portulacae 20 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Herba Asari 30 parts, Fructus Cnidii 5 parts, Radix Sophorae Flavescentis 20 parts, 80 mesh sieves are crossed after co-grinding, add 10 times amount soak by water 5 hours, then add 5 times amount soak by water 2 hours, natural cooling.
embodiment 3
Radix Sanguisorbae 30 parts, Radix Arnebiae (Radix Lithospermi) 22 parts, Herba Artemisiae Annuae 35 parts, 22 parts, Poria, Radix Ophiopogonis 18 parts, Herba Portulacae 15 parts, the Rhizoma Atractylodis Macrocephalae 16 parts, Herba Asari 25 parts, Fructus Cnidii 10 parts, Radix Sophorae Flavescentis 15 parts, 80 mesh sieves are crossed after co-grinding, add 10 times amount soak by water 5 hours, then add 5 times amount soak by water 2 hours, natural cooling.
embodiment 4
Radix Sanguisorbae 25 parts, Radix Arnebiae (Radix Lithospermi) 26 parts, Herba Artemisiae Annuae 30 parts, 26 parts, Poria, Radix Ophiopogonis 15 parts, Herba Portulacae 18 parts, the Rhizoma Atractylodis Macrocephalae 12 parts, Herba Asari 30 parts, Fructus Cnidii 8 parts, Radix Sophorae Flavescentis 20 parts, 80 mesh sieves are crossed after co-grinding, add 10 times amount soak by water 5 hours, then add 5 times amount soak by water 2 hours, natural cooling.
embodiment 5
Radix Sanguisorbae 25 parts, Radix Arnebiae (Radix Lithospermi) 26 parts, Herba Artemisiae Annuae 30 parts, 26 parts, Poria, Radix Ophiopogonis 10 parts, Herba Portulacae 20 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Herba Asari 30 parts, Fructus Cnidii 5 parts, Radix Sophorae Flavescentis 20 parts, 80 mesh sieves are crossed after co-grinding, add 10 times amount soak by water 5 hours, then add 5 times amount soak by water 2 hours, natural cooling.
embodiment 6
Radix Sanguisorbae 25 parts, Radix Arnebiae (Radix Lithospermi) 25 parts, Herba Artemisiae Annuae 35 parts, 24 parts, Poria, Radix Ophiopogonis 15 parts, Herba Portulacae 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Herba Asari 25 parts, Fructus Cnidii 9 parts, Radix Sophorae Flavescentis 18 parts, 80 mesh sieves are crossed after co-grinding, add 10 times amount soak by water 5 hours, then add 5 times amount soak by water 2 hours, natural cooling.
embodiment 7
1 method
1.1 case selections: include 60 routine patients with chronic eczema volunteers altogether in.
1.1.1 inclusive criteria
1) diagnostic criteria of chronic eczema is met; 2) 5% < skin lesion area < 30%; 3) age 15-73 one full year of life.
1.1.2 exclusion standard
1) there is the vitals serious change person that the other reasons beyond eczema causes; 2) dull-witted and psychotic, gravid woman; 3) system application glucocorticoid, immunosuppressant person in 2 weeks; 4) antihistaminic and external glucocorticoid person is used in 2 weeks.
1.1.3 standard is rejected
1) group and exclusion standard person is incorporated into through auditing not to be inconsistent; 2) uncomplaisance medication person or duration of test merge other active drugs person; 3) experimenter of test has namely been exited in non-medication or medication few (<10%), does not namely list in efficacy analysis.
1.2 EXPERIMENTAL DESIGN
Employing is random, final result person is blind, parallel control clinical trial design.Divide 2 groups at random by patient, accept the corresponding treatment of 21 days.Patient is assessed the clinical symptoms of patient and sign by same final result index evaluation person after the 21st day with treatment respectively before the treatment, and record in detail.Call-on back by phone was carried out to Patients on Recurrence situation in 4th month after treatment terminates.
1.3 trial drugs and therapeutic scheme
1.3.1 trial drug
The decoction liquor of the embodiment of the present invention 6.
Control drug: Radix Sanguisorbae 25 parts, 25 parts, the Radix Rehmanniae, Rhizoma Picrorhizae 35 parts, 24 parts, Poria, Radix Ophiopogonis 15 parts, Herba Portulacae 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Herba Asari 25 parts, Fructus Cnidii 9 parts, Radix Sophorae Flavescentis 18 parts, 80 mesh sieves are crossed after co-grinding, add 10 times amount soak by water 5 hours, add 5 times amount soak by water 2 hours again, natural cooling.
1.3.2 therapeutic scheme
Treatment group: the washing liquid becoming to contain crude drug amount 0.5g/ml by decoction liquor by warm water exchange, washout or immersion affected part 10min, every day 2 times, 21 days courses for the treatment of.
Matched group: the same treatment group of therapeutic scheme.
1.3.3 observation index and evaluation methodology
1.3.3.1 skin lesion area and severity scale
Adopt eczema area and Severity Index point system (Eczema Area and Severity Index, EASI).Whole body is divided into head/neck (H), upper limb (UL), trunk (T), lower limb (LL) 4 positions, within more than 8 years old, each site area of patient accounts for the ratio of whole body area, and head and neck calculates with 10%, upper limb 20%, trunk 30%, lower limb 40%.The ratio score value that skin lesion area accounts for each site area is 0 ~ 6, that is: 0 is without erythra, and 1 is <10%, and 2 be 10% ~ 19%, 3 be 20% ~ 49%, 4 be 50% ~ 69%, 5 be 70% ~ 89%, 6 is 90% ~ 100%.Clinical manifestation is divided into four, erythema (erythema, E), hard swollen (edema)/pimple (induration (edema)/papulation, I), exfoliation (excoriation, Ex), lichenization (1ichenification, L), respectively with 0 ~ 3 point of evaluation: 0=without; 1=is slight; 2=moderate; 3=severe.Calculate systemic ratio shared by ratio × each position that each position score value=(E+I+Ex+L) × skin lesion accounts for each site area, each position score value is added the total score being EASI skin lesion severity of symptom, and total score scope is 0 ~ 72 point.According to clinical symptoms and sign improve degree using therapeutic index as evaluation criteria, clinical efficacy to be roughly divided into be almost recovered, effective, effective and invalid level Four, therapeutic index=(after treatment front target skin lesion EASI-treatment target skin lesion EASI)/treatment front target skin lesion EASI × 100%.Be almost recovered: skin lesion disappears, transference cure, therapeutic index >=90%; Effective: skin lesion obviously disappears, symptom obviously disappears, therapeutic index 60% ~ 89%; Effective: skin lesion obviously disappears, symptom obviously disappears, therapeutic index 20% ~ 59%; Invalid: skin lesion disappears not obvious, symptom has no and alleviates or increase the weight of, therapeutic index <20%.Total effective rate=(recovery from illness number of cases+effective number of cases+effectively number of cases)/curative effect total cases × 100%.
1.3.3.2 relapse rate
Call-on back by phone was carried out to recovery from illness and effective Patients on Recurrence situation in after treatment terminates 4th month.Calculate relapse rate: relapse rate=(after the patient number of cases/21 day treatment of recurrence recovery from illness and the total number of cases of effective patient) × 100%.
2 results
2.1 total effective rates compare
The routine patient of case-data 60 is probabilistically assigned and enters two groups, wherein treatment group 30 people, matched group 30 people, and two groups of Genders, mean age, EASI are marked comparing difference not statistically significant (P>0.05).Do not have and can not complete experimenter.
To treat after 21 days total effective rate in table 1 for two groups.Treatment group compares with matched group total effective rate, has significant difference (P<0.05), shows that the Be very effective of Drug therapy skin chronic eczema provided by the invention is better than matched group medicine.
Table 1 respectively organizes total effective rate
| Recovery from illness | Effective | Effectively | Invalid | Total effective rate | |
| Treatment group | 15 | 7 | 6 | 2 | 93.3% |
| Matched group | 9 | 8 | 6 | 7 | 76.7% |
2.2 relapse rate
After 4 months, to treatment, within 21 days, recovery from illness and effective Patients Patients follow up a case by regular visits to afterwards in drug withdrawal.Two groups of patients, 4 months relapse rate comparative results are in table 2.Treatment group compares with matched group relapse rate, and treatment group relapse rate, significantly lower than matched group, shows that treatment by Chinese herbs eczema provided by the invention can treating both the principal and secondary aspects of a disease, determined curative effect.
Table 2 respectively organizes relapse rate
| Total number of persons | Recurrence | Do not recur | Relapse rate | |
| Treatment group | 22 | 1 | 21 | 4.5% |
| Matched group | 17 | 4 | 13 | 23.5% |
Claims (3)
1. treat the medicine of skin chronic eczema for one kind, it is characterized in that, be made up of the crude drug of following weight portion: Radix Sanguisorbae 20-30 part, Radix Arnebiae (Radix Lithospermi) 20-30 part, Herba Artemisiae Annuae 30-40 part, Poria 20-30 part, Radix Ophiopogonis 10-20 part, Herba Portulacae 10-20 part, Rhizoma Atractylodis Macrocephalae 10-20 part, Herba Asari 20-30 part, Fructus Cnidii 5-10 part, Radix Sophorae Flavescentis 10-20 part.
2. medicine according to claim 1, it is characterized in that, be made up of the crude drug of following weight portion: Radix Sanguisorbae 25-30 part, Radix Arnebiae (Radix Lithospermi) 22-26 part, Herba Artemisiae Annuae 30-35 part, Poria 22-26 part, Radix Ophiopogonis 15-18 part, Herba Portulacae 15-18 part, Rhizoma Atractylodis Macrocephalae 12-16 part, Herba Asari 25-30 part, Fructus Cnidii 8-10 part, Radix Sophorae Flavescentis 15-20 part.
3. medicine according to claim 2, it is characterized in that, be made up of the crude drug of following weight portion: Radix Sanguisorbae 25 parts, Radix Arnebiae (Radix Lithospermi) 25 parts, Herba Artemisiae Annuae 35 parts, 24 parts, Poria, Radix Ophiopogonis 15 parts, Herba Portulacae 15 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Herba Asari 25 parts, Fructus Cnidii 9 parts, Radix Sophorae Flavescentis 18 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510265782.6A CN104887785A (en) | 2015-05-24 | 2015-05-24 | Drug for treating chronic eczema of skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510265782.6A CN104887785A (en) | 2015-05-24 | 2015-05-24 | Drug for treating chronic eczema of skin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104887785A true CN104887785A (en) | 2015-09-09 |
Family
ID=54021027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510265782.6A Pending CN104887785A (en) | 2015-05-24 | 2015-05-24 | Drug for treating chronic eczema of skin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104887785A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040137084A1 (en) * | 2001-09-25 | 2004-07-15 | Ching-Hsiang Hsu | Treatment of allergic rhinitis |
| CN1795876A (en) * | 2004-12-21 | 2006-07-05 | 白彦萍 | Towel of freshening and cooling skin |
-
2015
- 2015-05-24 CN CN201510265782.6A patent/CN104887785A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040137084A1 (en) * | 2001-09-25 | 2004-07-15 | Ching-Hsiang Hsu | Treatment of allergic rhinitis |
| CN1795876A (en) * | 2004-12-21 | 2006-07-05 | 白彦萍 | Towel of freshening and cooling skin |
Non-Patent Citations (2)
| Title |
|---|
| 陈丽红: "化瘀祛湿法治疗慢性湿疹疗效观察", 《辽宁中医药大学学报》 * |
| 马丽萍等: "中药湿敷治疗急性、亚急性湿疹80例临床疗效观察", 《新疆中医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861274B (en) | External use traditional Chinese medicine for treating eczema | |
| CN100571753C (en) | A kind of antipsoriatics thing | |
| CN100518789C (en) | Medicine for treating cancer and preparing method therefor | |
| CN104288624A (en) | Pharmaceutical composition and application thereof | |
| CN103142959A (en) | Medicament for treating urticaria | |
| CN102319317B (en) | Traditional Chinese medicine composition for treating menstrual disorder and preparation method thereof | |
| CN104887785A (en) | Drug for treating chronic eczema of skin | |
| CN104887786A (en) | Application of drug in treatment of chronic eczema of skin | |
| CN104887803A (en) | Use of traditional Chinese medicine in treatment of eczema | |
| CN104887804A (en) | Traditional chinese medicine for treating eczema | |
| CN105343578A (en) | Medicine composition for treating haemorrhoids | |
| CN105412621A (en) | Method for preparing pharmaceutical composition for treating hemorrhoids | |
| CN106389972A (en) | Rhodomyrtus tomentosa wine for treating rheumatic diseases and preparation method thereof | |
| CN106620133A (en) | Medicinal liquor having functions of invigorating the kidney, strengthening Yang and expelling wind-damp and preparation method thereof | |
| CN103638229A (en) | Chinese medicinal lotion for treating eczema and preparation method thereof | |
| CN104491677A (en) | Preparation method of medicament for treating sexual dysfunction | |
| CN104248677A (en) | Traditional Chinese medicinal preparation for treating erythema multiforme | |
| CN103110722B (en) | Traditional Chinese medicine for treating chronic pelvic inflammatory disease and preparation method thereof | |
| CN104147463B (en) | A kind of medicine for treating psoriasis | |
| CN104815132A (en) | External lotion for treating low back and leg pain and preparation method | |
| CN105169342A (en) | Traditional Chinese medicine composition for treating eczema and preparation method thereof | |
| CN105194457A (en) | Chinese herba preparation for lymphangitis and preparation method thereof | |
| CN103933336A (en) | Traditional Chinese medicine combination for treating leucoderma | |
| CN103977214A (en) | External preparation for treating chronic pelvic inflammatory disease | |
| CN104306911A (en) | Traditional Chinese medicine for treating flatus vaginalis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150909 |